Myelodysplastic syndromes (MDS), especially refractory anemia (RA) are very heterogeneous diseases regarding their morphological, biological and clinical features. One important clinical problem is the difficulty of diagnosis. Soluble transferrin receptors (sTfRs) reflect the erythropoietic activity in the bone marrow (BM). To establish whether determination of serum sTfR could be useful for the differential diagnosis between RA and aplastic anemia (AA), we measured the serum sTfR concentrations, BM cellularity and BM erythroblast percentages in 14 untreated AA and 7 untreated RA patients. The serum sTfR levels of the RA patients (820.1 ± 402.8 ng/ml) were significantly higher than those of the AA patients (491.1 ± 195.2 ng/ml; p = 0.0207). However, the serum sTfR values of RA and AA patients also overlapped. A new index, the ‘sTfR-E index’ [the ratio of serum sTfR level (ng/ml) to BM cellularity (%) × BM erythroblasts (%)] is proposed, which is expected to reflect the number of transferrin receptors (TfR) on the cell membrane per BM erythroblast. The sTfR-E index values of the 7 RA patients (0.395 ± 0.234) were significantly lower than those of the 14 AA patients (2.669 ± 1.633; p = 0.0003). The sTfR-E index values of AA and RA patients overlapped only marginally. In conclusion, the sTfR-E index may be a useful new diagnostic tool to distinguish between AA and RA patients.

Keywords:
Aplastic anemia, Myelodysplastic syndrome, Refractory anemia, Soluble transferrin receptor
1.
Goasguen JE, Bennett JM: Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol 1992;19:4–13.
2.
Ganser A, Hoelzer D: Clinical course of myelodysplastic syndromes. Hematol Oncol Clin N Am 1992;6:607–617.
3.
Koeffler HP: Introduction: Myelodysplastic syndromes. Semin Hematol 1996;33:87–94.
4.
Barrett J, Saunthararajah Y, Molldrem J: Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000;37:15–29.
5.
Nand S, Godwin JE: Hypoplastic myelodysplastic syndrome. Cancer 1988;62:958–964.
6.
Kohgo Y, Niitsu Y, Kondo H, Kato J, Tsushima N, Sasaki K, Hirayama M, Numata T, Nishisato T, Urushizaki I: Serum transferrin receptor as a new index of erythropoiesis. Blood 1987;60:1955–1958.
7.
Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA: Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990;75:102–107.
8.
Weibel ER, Kistler GS, Scherle WF: Practical sterological methods for morphometric cytology. J Cell Biol 1966;30:23–38.
9.
Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH: Regulation of cellular iron metabolism by erythropoietin: Activation of iron regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood 1997;89:680–687.
10.
Skikne BS, Flowers CH, Cook JD: Serum transferrin receptor: A quantitative measure of tissue iron deficiency. Blood 1990;75:1870–1876.
11.
Kuiper-Kramer EPA, Coenen JLLM, Huisman CMS, Abbes A, Van Raan J, Van Eijk HG: Relationship between soluble transferrin receptors in serum and membrane-bound transferrin receptors. Acta Haematol 1998;99:8–11.
12.
Akira Matsuda, Masami Bessho, Shigehisa Mori, Tsutomu Takeuchi, Tohru Abe, Yoshihito Yawata, Hiraku Mori, Mitsuhiro Omine, Yuichi Nakamura, Shinpei Furusawa, Teiryo Maeda, Susumu Haginosita, Yoshihei Hirasawa, Eriko Kinugasa, Tadao Akizawa, Naohito Kawakami, Atsuo Nagata, Kunitake Hirashima: Diagnostic significance of serum soluble transferrin receptors in various anemic diseases: The first multi-institutional joint study in Japan. Haematologia 2002;32:225–238.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.